WO2005058313A1 - Utilisation de gaboxadol pour le traitement de l'insomnie - Google Patents

Utilisation de gaboxadol pour le traitement de l'insomnie Download PDF

Info

Publication number
WO2005058313A1
WO2005058313A1 PCT/DK2004/000861 DK2004000861W WO2005058313A1 WO 2005058313 A1 WO2005058313 A1 WO 2005058313A1 DK 2004000861 W DK2004000861 W DK 2004000861W WO 2005058313 A1 WO2005058313 A1 WO 2005058313A1
Authority
WO
WIPO (PCT)
Prior art keywords
gaboxadol
insomnia
oral dose
treatment
dose form
Prior art date
Application number
PCT/DK2004/000861
Other languages
English (en)
Inventor
Bjarke Ebert
Jonas Lundahl
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005058313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MXPA06006685A priority Critical patent/MXPA06006685A/es
Priority to CA002550610A priority patent/CA2550610A1/fr
Priority to EA200600989A priority patent/EA200600989A1/ru
Priority to JP2006544213A priority patent/JP2007515415A/ja
Priority to BRPI0415893-8A priority patent/BRPI0415893A/pt
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to EP04803014A priority patent/EP1720547A1/fr
Priority to AU2004298313A priority patent/AU2004298313A1/en
Publication of WO2005058313A1 publication Critical patent/WO2005058313A1/fr
Priority to IS8390A priority patent/IS8390A/is
Priority to IL176239A priority patent/IL176239A0/en
Priority to NO20063320A priority patent/NO20063320L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to the use of gaboxadol for the preparation of medicaments useful for the treatment of insomnia in a human patient, a method for treating insomnia in a human patient, and a pharmaceutical composition comprising an amount of gaboxadol being effective for the treatment of insomnia.
  • Gaboxadol (THIP or 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol) described in EP patent 0000338 Bl, and in EP Patent 0840601 Bl has shown great potential in the treatment of sleep disorders in general.
  • gaboxadol is able to increase sleep maintenance and to promote deep sleep, while having no disrupting influence on REM sleep.
  • the present inventors are the first to realize the usefullness of gaboxadol as an oral treatment of insomnia in human patients. Accordingly, no treatment regimen have been proposed for treatment of insomnia in human patients, no effects of cessation of treatment in human patients have been studied, and no abuse or dependency of treatment in human patients have been investigated.
  • gaboxadol is an effective treatment for insomnia in human patients, in particular primary insomnia.
  • gaboxadol has shown a significant improved effect in human patients suffering from impaired day time functioning, in particular such patients suffering from primary insomnia.
  • Impaired day time functioning may be due to suffering from a sleep disorder or any disease, disorder or condition leading to deprivation of sleep, or obstruction of sleep, such as primary insomnia, secondary insomnia, circadian rhythm sleep disorders, sleep disorders due to occassional stress, sleep apnea, narcolepsy, sleep paralysis, snoring, night terrors, night sweats, delayed sleep phase syndrome, depression, chronic tension type headache, fibromyalgia, neuropatic pain, chronic pain, alcoholic abuse, arthritis.
  • the objective of the invention is to provide an effective treatment of insomnia in a human patient, in particular primary insomnia and insomnia secondary to another mental disorder, a general medical condition or induced by a substance (secondary insomnia).
  • a further objective of the invention is to provide an effective treatment of insomnia in a human patient, without causing rebound insomnia upon cessation of treatment, in particular long-term treatment.
  • a further objective of the invention is to provide an effective treatment of insomnia in a human patient, without causing abuse or dependency of treatment, in particular long-term treatment.
  • the studies performed revealed that it was particular advantageous to administer gaboxadol at bedtime, such as from about 1 hour, for instance, from about Vz hour before going to sleep.
  • Gaboxadol has the general formula
  • glycol is intended to include any form of the compound, such as the base (zwitter ion), pharmaceutically acceptable salts, e.g. pharmaceutically acceptable acid addition salts, hydrates or solvates of the base or salt, as well as anhydrates, and also amorphous, or crystalline forms.
  • base zwitter ion
  • pharmaceutically acceptable salts e.g. pharmaceutically acceptable acid addition salts, hydrates or solvates of the base or salt, as well as anhydrates, and also amorphous, or crystalline forms.
  • insomnia is intended to mean a disorder characterised by abnormalities in the amount, quality and timing of sleep and includes circadian rhythm sleep disorders, sleep disorders due to occasional stress, primary insomnia and insomnia secondary to another mental disorder, a general medical condition or induced by a substance (hereafter referred to as secondary insomnia).
  • Primary insomnia is associated with complaint in initiating or maintaining, or nonrestorative sleep not exclusively occurring due to another mental disorder, physiological effects of a substance or a general medical condition.
  • Secondary insomnia is associated with complaint in initiating or maintaining, or nonrestorative sleep occurring due to another mental disorder, physiological effects of a substance or a general medical condition.
  • Such substance may be e.g. acethyl choline esterase inhibitors or beta blockers.
  • the treatment is typically given during less than a week (short term treatment), from 1 to 4 weeks (intermediate term treatment) or for a period exceeding 4 weeks (long-term treatment).
  • short term treatment from 1 to 4 weeks (intermediate term treatment) or for a period exceeding 4 weeks (long-term treatment).
  • long-term treatment is chronic treatment.
  • adults is intended to mean humans from 18 to 64 years.
  • children is intended to mean humans from 0 to 17 years.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amount of gaboxadol being effective for the treatment of insomnia.
  • Individual embodiments are primary insomnia and secondary insomnia.
  • the treatment is typically given during less than a week, from 1 week up to 4 weeks, or for a period exceeding 4 weeks.
  • the pharmaceutical composition is an oral dose form, such as a solid oral dose form, typically tablets or capsules, or a liquid oral dose form, such as a solution.
  • the pharmaceutical composition is a solid oral dose form, typically tablets or capsules.
  • gaboxadol is selected from the zwitter ion, typically a hydrate thereof, although the anhydrate is also suitable.
  • a typical embodiment is the zwitter ion monohydrate.
  • gaboxadol is selected from an acid addition salt, typically a pharmaceutically acceptable acid addition salt.
  • a typical embodiment is an organic acid addition salt, such as any one of the maleic, fumaric, benzoic, ascorbic, succmic, oxalic, bis- methylenesalicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic or theophylline acetic acid addition salts.
  • Another typical embodiment is an inorganic acid addition salt, such as any one of the hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric or nitric acid addition salts.
  • gaboxadol is in the form of the hydrochloric acid salt, the hydrobromic acid salt, or the zwitter ion monohydrate.
  • gaboxadol is crystalline, such as the crystalline hydrochloric acid salt, the crystalline hydrobromic acid salt, or the crystalline zwitter ion monohydrate.
  • the amount of gaboxadol in the composition ranges from 2.5 mg to 20 mg, such as 5 mg to 15 mg. The amount of gaboxadol is calculated based on the free base form. In a typical embodiment, the amount of gaboxadol in the composition is 2.5 mg. In a further typical embodiment, the amount of gaboxadol in the composition is 5 mg. In a further typical embodiment, the amount of gaboxadol in the composition is 7.5 mg.
  • the amount of gaboxadol in the composition is 10 mg. In a further typical embodiment, the amount of gaboxadol in the composition is 12.5 mg. In a further typical embodiment, the amount of gaboxadol in the composition is 15 mg.
  • the present invention relates to a method for treating insomnia in a human patient in need thereof comprising administering to said patient an amount of gaboxadol per day, said amount being effective for the treatment of insomnia.
  • Typical embodiments of gaboxadol are selected from an acid addition salt, such as a pharmaceutically acceptable acid addition salt, e.g. selected from the hydrochloride or hydrobromide salt; or a zwitter ion hydrate, such as the zwitter ion monohydrate; or the zwitter ion anhydrate.
  • an acid addition salt such as a pharmaceutically acceptable acid addition salt, e.g. selected from the hydrochloride or hydrobromide salt
  • a zwitter ion hydrate such as the zwitter ion monohydrate; or the zwitter ion anhydrate.
  • Typical embodiments of the effective amount of gaboxadol ranges from 2.5 mg to 20 mg, such as 5 mg to 15 mg of gaboxadol per day. Most conveniently, gaboxadol is in a crystalline form.
  • Typical embodiments of insomnia are selected from patients with primary insomnia or secondary insomnia.
  • the patient may be any patient suffering from insomnia, and is selected from children, adults, or elderly.
  • Gaboxadol is administered as an oral dose form, such as a solid oral dose form, typically tablets or capsules, or as a liquid oral dose form. Gaboxadol is most conveniently administered orally in unit dosage forms such as tablets or capsules, containing the active ingredient in an amount from about 2.5 to about 20 mg, e.g. from about 5 to about 15 mg.
  • Patients requiring short-term treatment are typically patients suffering from circadian rhythm sleep disorders or sleep disorders due to occasional stress.
  • Patients requiring intermediate, long-term or chronic treatment are typically patients suffering from primary insomnia or secondary insomnia.
  • the present invention relates to use of gaboxadol for preparing a medicament for treating insomnia in a human patient, h particular the medicament comprises an amount of gaboxadol being effective for the treatment of insomnia.
  • the present invention relates to use of gaboxadol for preparing a medicament for treating primary insomnia in an adult or elderly human patient, wherein said medicament comprises an oral dose form comprising 5 to 15 mg of gaboxadol to be administered once daily from about 1 hour before bedtime up to bedtime.
  • gaboxadol is administered from about Vz hour to 45 minutes before bedtime up to bedtime, such as from 0 to 45 minutes before bedtime, e.g. from 0 to 30 minutes before bedtime, or from 5 to 20 minutes before bedtime. Any one of the embodiments of gaboxadol may be used.
  • the treatment may be intermediate, long-term or chronic treatment.
  • gaboxadol is in the form of an acid addition salt, or a zwitter ion hydrate or zwitter ion anhydrate.
  • gaboxadol is in the form of the pharmaceutically acceptable acid addition salt selected from the hydrochloride or hydrobromide salt, or in the form of the zwitter ion monohydrate.
  • the effective amount ranges from 2.5 mg to 20 mg of gaboxadol calculated as the base.
  • the gaboxadol is in a crystalline form.
  • Further embodiments of the medicament comprises an effective amount of gaboxadol from 2.5 mg to 20 mg, such as 5 mg to 15 mg, e.g. 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.
  • a typical embodiment being 5 mg to 15 mg of crystalline gaboxadol, such as the hydrochloride of gaboxadol.
  • a typical embodiment is use of gaboxadol as the hydrochloride for preparing a medicament comprising an effective amount of the gaboxadol from 5 mg to 15 mg, for treating insomnia in a human patient.
  • the human patient to be treated with gaboxadol may in fact be any subject of the human population, male or female, which maybe divided into children, adults, or elderly. Any one of these patient groups relates to an embodiment, thus, a typical embodiment is use of Gaboxadol for preparing a medicament comprising an effective amount of the Gaboxadol from 2.5 mg to 20 mg, for treating insomnia, such as primary or secondary insomnia, in an elderly human patient.
  • the medicament is an oral dose form.
  • the medicament is a solid oral dose form, such as tablets or capsules, or a liquid oral dose form.
  • a typical embodiment is use of gaboxadol for preparing a medicament in an oral dose form comprising an effective amount of the gaboxadol from 2.5 mg to 20 mg, for treating insomnia, such as primary or secondary insomnia, in a human patient, such as an elderly human patient.
  • the treatment is short-term treatment. In a further embodiment the treatment is intermediate term treatment. In a further embodiment the treatment is long term treatment. In a further embodiment the treatment is chronic treatment.
  • gaboxadol for preparing a medicament, such as in an oral dose form, comprising an effective amount of the gaboxadol from 2.5 mg to 20 mg, for long term treatment of insomnia, such as primary or secondary insomnia, in a human patient, such as an elderly human patient.
  • the present invention relates to a method for treating primary insomnia in an adult or elderly human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day wherein gaboxadol is administered from about 1 hour before bedtime up to bedtime.
  • gaboxadol is administered from about l hour to 45 minutes before bedtime up to bedtime, such as from 0 to 45 minutes before bedtime, e.g. from 0 to 30 minutes before bedtime, or from 5 to 20 minutes before bedtime. Any one of the embodiments of gaboxadol maybe used.
  • the treatment may be intermediate, long-term or chronic treatment.
  • the present invention relates to a method of improving day time functioning in a human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day.
  • the present invention relates to a method of treating impaired day time functioning in a human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day.
  • Such human patient maybe suffering from a sleep disorder or any disease, disorder or condition leading to deprivation of sleep, or obstruction of sleep, such as primary insomnia, secondary insomnia, circadian rhythm sleep disorders, sleep disorders due to occassional stress, sleep apnea, narcolepsy, sleep paralysis, snoring, night terrors, night sweats, delayed sleep phase syndrome, depression, chronic tension type headache, fibromyalgia, neuropatic pain, chronic pain, alcoholic abuse, or arthritis.
  • a sleep disorder or any disease, disorder or condition leading to deprivation of sleep, or obstruction of sleep such as primary insomnia, secondary insomnia, circadian rhythm sleep disorders, sleep disorders due to occassional stress, sleep apnea, narcolepsy, sleep paralysis, snoring, night terrors, night sweats, delayed sleep phase syndrome, depression, chronic tension type headache, fibromyalgia, neuropatic pain, chronic pain, alcoholic abuse, or arthritis.
  • the invention concerns in one embodiment a method of improving day time functioning in a human patient suffering from primary insomnia in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day.
  • gaboxadol may be used as the base (i.e. the zwitter ion) or as a pharmaceutically acceptable acid addition salt thereof or as an anhydrate or hydrate or solvate of such salt or base.
  • the salts of the compound used in the invention are salts formed with non-toxic organic or inorganic acids.
  • organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p- amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8- halotheophyllines, for example 8-bromo-theophylline.
  • Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
  • Gaboxadol may also be used as the zwitter ion, e.g. the mono hydrate thereof.
  • the acid addition salts according to the invention may be obtained by treatment of gaboxadol with the acid in an inert solvent followed by precipitation, isolation and optionally re-crystallisation by known methods and if desired micronisation of the crystalline product by wet or dry milling or another convenient process, or preparation of particles from a solvent-emulsification process. Suitable methods are described in EP patent 0000338.
  • Precipitation of the salt is typically carried out in an inert solvent, e.g. an inert polar solvent such as an alcohol (e.g. ethanol, 2-propanol and n-propanol), but water or mixtures of water and inert solvent may also be used.
  • an inert solvent e.g. an inert polar solvent such as an alcohol (e.g. ethanol, 2-propanol and n-propanol), but water or mixtures of water and inert solvent may also be used.
  • gaboxadol should be administered orally, and it may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions.
  • gaboxadol is administered in the form of a solid pharmaceutical entity, suitably as a tablet or a capsule.
  • Tablets may thus be prepared by mixing the active ingredients with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a convenient tabletting machine.
  • adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive such as colourings, aroma, preservatives, etc. may also be used provided that they are compatible with the active ingredients.
  • gaboxadol A suitable formulation of gaboxadol is described in WO 02/094225 filed May 17, 2002. Without limiting the invention in any way, it is intended that any one of the aspects or embodiments of this patent application is suitable embodiments of the medicament or pharmaceutical compositions herein.
  • Doses are 2.5 to 20 mg per day as previously stated. The doses are not different between the patient diagnoses or treatment durations. Effect is confirmed for short-term treatment in studies using acute treatment in healthy subjects exposed to a phase advance model. Assessment of effect on insomnia during intermediate term treatment duration is performed in primary insomnia patients using treatment duration up 4 weeks. Long term or chronic treatment is assessed in 12 months safety studies. Patient populations includes primary insomnia patients with age range 18-65 yrs (adults) and 65 and above (elderly).
  • gaboxadol improves sleep maintenance as measured by polysomnograph (PSG).
  • PSG polysomnograph
  • Sleep maintenance is measured by either of parameters wakefulness after sleep onset, number of awakenings after sleep onset or total sleep time.
  • Data from the clinical study including a phase advance model in healthy subjects also demonstrated that subjects perceive this effect as decreased wakefulness.
  • the effect was observed at doses as low as 5 mg per day.
  • gaboxadol facilitated sleep initiation in studies conducted using primary insomnia patients and subjects in a phase advance model. In these studies, the effect was also confirmed by the patients own feeling of the sleep initiation. Based both on PSG and on subjective diary recording, gaboxadol doses of 5 to 15 mg are required to achieve effect in adults and elderly (gaboxadol was administered from V2 hour before bedtime up to immediately before going to bed).
  • gaboxadol induced a dose-dependent increase in duration of slow wave sleep (SWS), that is, stages 3 and 4, which is considered the deepest stage of sleep.
  • SWS slow wave sleep
  • the effect ranged between +15 and 46% compared to placebo.
  • the enhancement of SWS observed in the EEG was identified in the spectral analysis as an increase of slow wave activity with similar effect range as described above for slow wave sleep. Improvement in daytime function
  • the daytime performance (used interchangeably with daytime function) in adult (18-65yrs) primary insomnia patients (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition, DSM IN-TR) has been assessed in a 3 week placebo controlled parallel group, outpatient study.
  • the performance was measured with standardised questions using a 100 point Visual analogue scale (NAS).
  • NAS Visual analogue scale
  • Patients responses were recorded in a diary in the evening on the day after each treatment night (gaboxadol was administered about X A hour before bedtime).
  • daytime function was recorded once weekly using the Sheehan disability scale (ref.Sheehan et al 1996, The measurement of disability. International Clinical Psychopharamcology;ll(suppl 3), 89-95).
  • gaboxadol in doses 5, 10 and 15 mg significantly improve daytime performance. The effect is more pronounced during week 2 and 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode de traitement de l'insomnie chez des patients humains nécessitant un tel traitement qui consiste à administrer une dose journalière de gaboxadol, ladite dose étant efficace pour le traitement de l'insomnie.
PCT/DK2004/000861 2003-12-18 2004-12-14 Utilisation de gaboxadol pour le traitement de l'insomnie WO2005058313A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2004298313A AU2004298313A1 (en) 2003-12-18 2004-12-14 Use of gaboxadol for treating insomnia
CA002550610A CA2550610A1 (fr) 2003-12-18 2004-12-14 Utilisation de gaboxadol pour le traitement de l'insomnie
EA200600989A EA200600989A1 (ru) 2003-12-18 2004-12-14 Применение габоксадола для лечения бессонницы
JP2006544213A JP2007515415A (ja) 2003-12-18 2004-12-14 不眠症の治療にガボクサドールを使用する方法
BRPI0415893-8A BRPI0415893A (pt) 2003-12-18 2004-12-14 métodos para tratar insÈnia em um paciente humano em necessidade do mesmo, para tratar insÈnia primária em um paciente humano adulto ou idoso em necessidade do mesmo e para melhorar o funcionamento no horário diurno em um paciente humano em necessidade do mesmo, uso do gaboxadol, e, composição farmacêutica
MXPA06006685A MXPA06006685A (es) 2003-12-18 2004-12-14 Uso de gaboxadol para tratar el insomnio.
EP04803014A EP1720547A1 (fr) 2003-12-18 2004-12-14 Utilisation de gaboxadol pour le traitement de l'insomnie
IS8390A IS8390A (is) 2003-12-18 2006-03-30 Notkun á gaboxadóli við meðhöndlun á svefnleysi
IL176239A IL176239A0 (en) 2003-12-18 2006-06-11 Use of gaboxadol for treating insomnia
NO20063320A NO20063320L (no) 2003-12-18 2006-07-18 Anvendelse av gaboxadol for behandling av insomni

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKDKPA200301877 2003-12-18
DKPA200301877 2003-12-18

Publications (1)

Publication Number Publication Date
WO2005058313A1 true WO2005058313A1 (fr) 2005-06-30

Family

ID=34684447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000861 WO2005058313A1 (fr) 2003-12-18 2004-12-14 Utilisation de gaboxadol pour le traitement de l'insomnie

Country Status (17)

Country Link
EP (1) EP1720547A1 (fr)
JP (1) JP2007515415A (fr)
KR (1) KR20060103335A (fr)
CN (1) CN1893942A (fr)
AR (1) AR047154A1 (fr)
AU (1) AU2004298313A1 (fr)
BR (1) BRPI0415893A (fr)
CA (1) CA2550610A1 (fr)
EA (1) EA200600989A1 (fr)
IL (1) IL176239A0 (fr)
IS (1) IS8390A (fr)
MX (1) MXPA06006685A (fr)
NO (1) NO20063320L (fr)
SG (1) SG133601A1 (fr)
TW (1) TW200528098A (fr)
WO (1) WO2005058313A1 (fr)
ZA (1) ZA200602762B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906953A1 (fr) * 2005-04-29 2008-04-09 H. Lundbeck A/S Formes de sels acides et de sels basiques de gaboxadol
US8236958B2 (en) 2004-01-30 2012-08-07 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
WO2019055369A1 (fr) * 2017-09-12 2019-03-21 Ovid Therapeutics Inc. Utilisation de gaboxadol dans le traitement de la narcolepsie
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002813A1 (fr) * 1995-07-13 1997-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistes non allosteriques de gabaa destines a traiter des troubles du sommeil
WO2002094225A1 (fr) * 2001-05-21 2002-11-28 H. Lundbeck A/S Preparations granulaire de gaboxadol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002813A1 (fr) * 1995-07-13 1997-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistes non allosteriques de gabaa destines a traiter des troubles du sommeil
EP0840601B1 (fr) * 1995-07-13 2001-10-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thip pour traiter des troubles du sommeil
WO2002094225A1 (fr) * 2001-05-21 2002-11-28 H. Lundbeck A/S Preparations granulaire de gaboxadol

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"GABA-A agonist in trial for insomnia", PHARMACEUTICAL JOURNAL, ISSN: 0031-6873 CODEN: PHJOAV, vol. 271, 11 October 2003 (2003-10-11), pages 488, XP008045128 *
FAULHABER, JOHANNES ET AL: "The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans", PSYCHOPHARMACOLOGY (BERLIN) , 130(3), 285-291 CODEN: PSCHDL; ISSN: 0033-3158, 1997, XP008045123 *
LANCEL, MARIKE ET AL: "Effect of the GABAA agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects", AMERICAN JOURNAL OF PHYSIOLOGY , 281(1, PT. 1), E130-E137 CODEN: AJPHAP; ISSN: 0002-9513, 2001, XP008045114 *
MATHIAS, STEFAN ET AL: "The GABAA agonist gaboxadol improves the quality of post-nap sleep", PSYCHOPHARMACOLOGY (BERLIN, GERMANY) , 157(3), 299-304 CODEN: PSCHDL; ISSN: 0033-3158, 2001, XP008045113 *
See also references of EP1720547A1 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236958B2 (en) 2004-01-30 2012-08-07 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
EP1906953A1 (fr) * 2005-04-29 2008-04-09 H. Lundbeck A/S Formes de sels acides et de sels basiques de gaboxadol
EP1906953A4 (fr) * 2005-04-29 2009-05-20 Lundbeck & Co As H Formes de sels acides et de sels basiques de gaboxadol
WO2019055369A1 (fr) * 2017-09-12 2019-03-21 Ovid Therapeutics Inc. Utilisation de gaboxadol dans le traitement de la narcolepsie
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11090293B2 (en) 2018-09-20 2021-08-17 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome

Also Published As

Publication number Publication date
KR20060103335A (ko) 2006-09-28
SG133601A1 (en) 2007-07-30
EP1720547A1 (fr) 2006-11-15
ZA200602762B (en) 2007-06-27
MXPA06006685A (es) 2006-08-23
CN1893942A (zh) 2007-01-10
IS8390A (is) 2006-03-30
CA2550610A1 (fr) 2005-06-30
BRPI0415893A (pt) 2007-01-09
AU2004298313A1 (en) 2005-06-30
IL176239A0 (en) 2006-10-05
EA200600989A1 (ru) 2006-10-27
NO20063320L (no) 2006-07-18
TW200528098A (en) 2005-09-01
JP2007515415A (ja) 2007-06-14
AR047154A1 (es) 2006-01-11

Similar Documents

Publication Publication Date Title
AU723954B2 (en) Non-allosteric gabaA agonists for treating sleep disorders
JP3984787B2 (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US20080269278A1 (en) Treatment of Impaired Respiratory Function with Gaboxadol
HU217136B (hu) Riluzol alkalmazása Parkinson-kór és Parkinson-szindrómák kezelésére szolgáló gyógyszerkészítmények előállítására
EP2717698A1 (fr) Antihistaminiques combinés à des compléments alimentaires pour améliorer la santé
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
EP1154795A1 (fr) Methode permettant de traiter et de diagnostiquer le syndrome des impatiences des membres inferieurs et dispositif correspondant
US20050137222A1 (en) Treatment of insomnia in human patients
EP1720547A1 (fr) Utilisation de gaboxadol pour le traitement de l'insomnie
JP2003511410A (ja) 肥満症の治療のためのモルホリノール誘導体
JP2007515415A6 (ja) 不眠症の治療にガボクサドールを使用する方法
CA2572302A1 (fr) Traitement de douleur neuropathique, de fibromyalgie ou de polyarthrite rhumatoide
JPH0196131A (ja) 睡眠障害および鬱病を治療するためのある種の化合物の使用
EP0725640A1 (fr) Utilisation de la lobeline dans le traitement de symptomes de sevrage de nicotine
JPH11513386A (ja) β−受容体遮断薬とオピオイドとの新規な組合せ物
EP1611901B1 (fr) Medicament destiné à prevenir ou à traiter les grincements de dents
AU736514B2 (en) Non-allosteric gabaa agonists for treating sleep disorders
US20190008188A1 (en) Antihistamines Combined with Dietary Supplements for Improved Health
JP2022529290A (ja) 呼吸性不整脈を処置するための方法および組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037243.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 546261

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006500677

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006/02762

Country of ref document: ZA

Ref document number: 200602762

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1200600897

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 176239

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006544213

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006685

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 06058017

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067011921

Country of ref document: KR

Ref document number: 2550610

Country of ref document: CA

Ref document number: 2144/CHENP/2006

Country of ref document: IN

Ref document number: 200600989

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004803014

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004298313

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004298313

Country of ref document: AU

Date of ref document: 20041214

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004298313

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067011921

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004803014

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415893

Country of ref document: BR